Piper Sandler keeps Overweight on OPKO Health after $722 million LabCorp deal

what happened

Piper Sandler reaffirmed its Overweight rating on OPKO Health shares and lifted its 12-month price target to $4.00. Data published by TradingView, which cites Benzinga, puts the implied upside at 148.4% from the October 15 close of $1.61.

The catalyst is a transaction under which OPKO plans to hand its remaining BioReference laboratory testing unit to LabCorp for $722 million. Extra revenue could follow from sales of the 4Kscore test. The analysts argue the deal will strengthen the company's financial position and simplify its operations.

Analysts estimate pro forma cash of roughly $1.15 billion after the transaction, which would improve liquidity and leave room for future investment.

why it matters

Selling a non-core unit for a sizeable sum and adding cash to the balance sheet is typically read as a positive for a small-cap stock, where balance-sheet strength often drives sentiment. Investors will watch whether the deal closes on schedule and how revenue from the 4Kscore test develops.

market impact

OPKO Health: the unit sale and higher cash reserves support the shares, per the analyst note

tags

instruments